News

Silence Therapeutics reports first half results

Silence Therapeutics Plc, which is developing siRNA-based therapies and a delivery platform, reported that its half-year revenue for the period ended June 2008 fell to £124,338 from £1,268,837 a year earlier. However, it said that its turnover for the full year would be similar to the £4 million sales it generated in 2007, “thereby ensuring a healthy year-end cash balance.”

Pharming to seek FDA approval for Rhucin

Pharming Group NV of the Netherlands said that it plans to submit a biologic licence application (BLA) with the US Food and Drug Administration for its lead drug, Rhucin, by the end of 2008.

Intercytex looks ahead to BLA for its lead wound product

The UK regenerative medicine company, Intercytex Group Plc, is moving forward with a pivotal Phase 3 trial of its lead product for chronic wounds and anticipates filing a biologic licence application for the product with the US Food and Drug Administration in the second half of 2009.

New class of antibiotics may subdue MRSA

Research published in the journal, Science, and financially supported by the Wellcome Trust, describes how a new class of antibiotics could be developed to treat multi-drug resistant Staphylococcus aureus (MRSA).